Expression profiling predicts outcome in breast cancer.

Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73

Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer (2007) 3.16

Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res (2003) 3.13

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A (2005) 1.82

A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78

Spurious spatial periodicity of co-expression in microarray data due to printing design. Nucleic Acids Res (2003) 1.61

Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res (2008) 1.59

Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One (2009) 1.56

Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 1.48

Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer (2010) 1.46

Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer. PLoS One (2015) 1.40

Extracting insights from the shape of complex data using topology. Sci Rep (2013) 1.40

Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics (2006) 1.27

High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics (2010) 1.27

Array-CGH and breast cancer. Breast Cancer Res (2006) 1.26

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18

Sparse representation for classification of tumors using gene expression data. J Biomed Biotechnol (2009) 1.18

Validation of computational methods in genomics. Curr Genomics (2007) 1.18

Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights (2010) 1.11

Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep (2012) 1.08

Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer (2010) 1.07

Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch (2006) 1.05

Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome. BMC Genomics (2007) 1.05

The use of transcriptomic biomarkers for personalized medicine. Heart Fail Rev (2007) 1.03

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer (2014) 1.01

A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A (2010) 1.01

Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol (2005) 1.00

Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol (2011) 0.91

Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis. Ann Oncol (2014) 0.90

Data mining in genomics. Clin Lab Med (2008) 0.90

Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. J Matern Fetal Neonatal Med (2008) 0.85

Targeted antitumour therapy--future perspectives. Br J Cancer (2005) 0.81

Gene expression profiling: from microarrays to medicine. J Clin Immunol (2004) 0.80

Significance of rat mammary tumors for human risk assessment. Toxicol Pathol (2014) 0.80

Identifying genes progressively silenced in preneoplastic and neoplastic liver tissues. Int J Comput Biol Drug Des (2010) 0.79

[Expression analyses for rheumatoid arthritis]. Z Rheumatol (2008) 0.77

Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Adv Biomed Res (2016) 0.76

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer. Biomark Insights (2016) 0.75

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. J Pathol Clin Res (2016) 0.75

Tumor Phenotype and Gene Expression During Early Mammary Tumor Development in Offspring Exposed to Alcohol In Utero. Alcohol Clin Exp Res (2016) 0.75

Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. Front Endocrinol (Lausanne) (2015) 0.75

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Res Treat (2016) 0.75

Occurrence of cancer at multiple sites: towards distinguishing multigenesis from metastasis. Biol Direct (2008) 0.75

Microarray technology and its effect on breast cancer (re)classification and prediction of outcome. Breast Cancer Res (2003) 0.75

The highly expressed COL4A1 genes contributes to the proliferation and migration of the invasive ductal carcinomas. Oncotarget (2017) 0.75

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34

Expression profiling to predict outcome in breast cancer: the influence of sample selection. Breast Cancer Res (2002) 1.72

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15

A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55

Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85

Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39

A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36

A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67

Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53

Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol (2007) 6.43

Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04

Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74

Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72

Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67

Rosetta error model for gene expression analysis. Bioinformatics (2006) 4.67

Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29

Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24

Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics (2004) 4.09

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07

Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol (2011) 4.02

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01

Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet (2006) 3.96

Effects of atmospheric ozone on microarray data quality. Anal Chem (2003) 3.93

Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70

Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70

Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med (2011) 3.68

Microarray standard data set and figures of merit for comparing data processing methods and experiment designs. Bioinformatics (2003) 3.33

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07

MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res (2011) 3.02

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91

A network view of disease and compound screening. Nat Rev Drug Discov (2009) 2.90

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65

An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64

Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34

Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26

Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood (2006) 2.18

Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14

Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int (2002) 2.12

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09

A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics (2005) 2.08

EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05

[Categorization of occult tumour cells in lymph nodes in patients with colon cancer not reliable enough]. Ned Tijdschr Geneeskd (2011) 2.03

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97

Cross-validated Cox regression on microarray gene expression data. Stat Med (2006) 1.90

Developing predictive molecular maps of human disease through community-based modeling. Nat Genet (2012) 1.88

Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol (2006) 1.87

T lymphocyte activation gene identification by coregulated expression on DNA microarrays. Genomics (2004) 1.86

Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) 1.84

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81

Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet (2013) 1.80

Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A (2007) 1.79

The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2005) 1.73

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73

Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol (2007) 1.69

Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res (2006) 1.69

microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol (2010) 1.69

A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res (2002) 1.64

Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60